Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.78, read 2026-11-01
Ethical does not pass the values gate
Price15.70 USD
Fair value18.75
Ethical score70.0/100
Value readUndervaluedas of 3 Nov 2026
Our investment reviews on this name
2026-08-09Read Markup10.72+46.5% to today ✓Distribution gives way to Markup
2026-07-02Read Distribution10.99+42.9% to today First review on file: Distribution
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Perrigo Company plc holds its Markup at $15.70. Consolidating, no directional conviction, held for 41 days.
As held on the ledger · 2026-11-03
Phase
Markup
Quantitative state
Consolidating, no directional conviction, held for 41 days
Price at the screen
$15.70
Valuation
N/A trailing · 6.85 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.69
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
42.65%
Below 33%
Interest-bearing debt is 42.6% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
13.41%
Below 49%
Money owed to the company is 13.4% of assets, under the 49% limit.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Perrigo's business is in a permissible area, but its interest-bearing debt is about 43% of the company, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-11-04. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when PRGO's ethical verdict changes
Today PRGO does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The quantitative screen above is arithmetic. Separately, community boycott lists cite this company: Documented on AFSC Investigate. The desk records that flag here without folding it into the verdict: the screen measures the balance sheet, the overlay informs the conscience, and they are different judgements that belong to different owners. The second one is yours.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Undervalued vs our fair value, as of 3 Nov 2026: it trades at roughly a 16% discount to our $18.75 fair value.
Fair value range in USD, drawn from the 2026-11-03 screen. The gold marker is the market price at the same screen. A 16.3% discount to the base estimate.
Where our models see it going: fair-value estimate $18.75, with a range of $18.75 to $31.06, dated to the 2026-11-03 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Cheap label on a business losing ground
Pick up a packet of paracetamol or a cough remedy at the chemist and the odds are decent it comes from Perrigo's factories. Yet the numbers tell a different story. Revenue is shrinking at seven percent a year, margins have collapsed to minus forty four percent and return on equity sits at minus fifty two percent, so the apparent seventy four percent margin of safety at ten dollars seventy two simply reflects a firm that is eating itself.
We pass because a forward multiple of four point five times cannot disguise the absence of growth or any visible moat. Four analysts see a median target of sixteen dollars but offer no consensus rating, which matches our own view that this is not an opportunity. The ethical screen is cleared, yet clean governance does not fix a business that is contracting.
The real risk sits in the assumption that losses will turn around without visible catalysts or pricing power. Low multiples on deteriorating operations often signal value traps rather than bargains, and nothing in the current trajectory suggests that pattern has been broken.
Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: its business and earnings are exposed to Ireland and to currency swings; as a drug manufacturers - specialty & generic name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
PRGO trades on the NYSE (the company is based in Ireland). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-04Markup$15.70-0.5%Entry 16
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are down 57%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (4 analysts) rates it none, with a mean price target of $16. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-03Markup$15.78+0.0%Entry 15
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are down 57%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (4 analysts) rates it none, with a mean price target of $16. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-02Markup$15.78+0.0%Entry 14
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are down 57%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (4 analysts) rates it none, with a mean price target of $16. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-01Markup$15.78-1.1%Entry 13
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 1.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are down 57%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (4 analysts) rates it none, with a mean price target of $16. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-31Markup$15.96+0.0%Entry 12
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are down 57%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (4 analysts) rates it none, with a mean price target of $16. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-30Markup$15.96+0.0%Entry 11
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are down 57%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (4 analysts) rates it none, with a mean price target of $16. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-29Markup$15.96-2.5%Entry 10
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 2.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are down 57%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (4 analysts) rates it none, with a mean price target of $16. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-28Markup$16.37+0.0%Entry 9
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are down 57%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (4 analysts) rates it none, with a mean price target of $16. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-23Markup$16.37+2.6%Entry 8
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 2.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are down 57%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (4 analysts) rates it none, with a mean price target of $16.
2026-10-16Markup$15.95+17.6%Entry 7
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 17.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 57%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (4 analysts) rates it none, with a mean price target of $16.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
